Peptide Mass Spec Interpretation: A Practical Guide

Interpreting a peptide mass spectrum comes down to three questions. What is the intact mass, which fragment ions support the sequence, and which peaks remain unexplained? Read the precursor first, convert its m/z and charge state to a neutral mass, then use the MS/MS fragment ladder to confirm or reject the expected sequence. This guide walks through that order for analytical and quality-control work. For Research Use Only. Not for human or veterinary use.

TL;DR

• The x-axis of a spectrum is mass-to-charge (m/z) and the y-axis is relative intensity, so a peak position is never a mass until you know the charge state.
• Calculate the neutral mass from the precursor m/z and charge, compare it with the theoretical mass of the expected sequence, and only then interpret fragments.
• In MS/MS, b-ions (N-terminal) and y-ions (C-terminal) form ladders, and the gaps between consecutive peaks correspond to residue masses.
• Unassigned peaks, unexpected modifications and incomplete fragmentation are the most common reasons a sequence assignment is wrong.
• Record the instrument method, the assignment logic and the batch identifier next to the Certificate of Analysis (COA), so the result can be reviewed later.

Table of Contents

• What a peptide mass spectrum shows
• Step 1: Read the precursor, charge state and neutral mass
• Step 2: Understand how peptides fragment
• Step 3: Verify the sequence against the ladder
• Step 4: Choose how to interpret: database search, de novo or mapping
• Step 5: Interpret modifications and ambiguity
• Common errors in peptide MS/MS interpretation
• Documenting results for quality control
• Perspective
• Sourcing documented peptides for your analysis
• FAQ
• Sources

What a peptide mass spectrum shows

A mass spectrum plots ion signals against mass-to-charge ratio. As Chemistry LibreTexts describes it, the horizontal axis is m/z and the vertical axis is ion intensity or relative abundance. Each line corresponds to an ion at a particular m/z, taller lines mean more of that ion formed, and the tallest peak, the base peak, is set to 100%.

Two points follow from this and cause most beginner mistakes.

1. Intensity is relative, not absolute. A peak at 100% in one spectrum says nothing about how it compares with the base peak in another run. Compare spectra only with matched acquisition settings.
2. The axis is m/z, not mass. Electrospray ionization tends to produce multiply charged ions from molecules with several polar sites, as a review of charge-state determination in ESI-MS points out. A peak at m/z 500 may be a 1+ ion of a 499 Da species or a 3+ ion of a roughly 1,497 Da species.

There are usually two kinds of spectra in a peptide dataset. A full-scan (MS1) spectrum shows the intact peptide ions, often in several charge states. A tandem (MS/MS) spectrum isolates one precursor, fragments it and records the pieces. You read the first to establish identity at the level of mass, and the second to test the sequence.

Step 1: Read the precursor, charge state and neutral mass

Start with the MS1 spectrum and find the cluster of peaks that belongs to your peptide. A peptide is not a single line. Carbon-13 and other heavy isotopes create an isotopic envelope, and the spacing between neighboring peaks in that envelope reveals the charge. Peaks spaced by about 1.0 m/z indicate a 1+ ion, about 0.5 indicate 2+, and about 0.33 indicate 3+.

For a positively charged ion containing only added protons, [M + zH]^z+, use the charge number (z) and monoisotopic m/z to calculate the neutral monoisotopic mass:

M = (m/z × z) − (z × 1.00728)

The constant is the mass of a proton. Other adducts, including sodium and potassium, and other ionization modes require the corresponding mass adjustment. An illustrative calculation, with invented numbers: a monoisotopic peak at m/z 500.250 with z = 2 gives 1,000.500 − 2.015 = 998.485 Da. If the expected sequence has a theoretical monoisotopic mass of 998.48 Da, the intact-mass check passes.

When a peptide appears in several charge states, such as 2+, 3+ and 4+, each state should return the same neutral mass. Agreement across charge states is one of the quickest internal consistency checks available, and disagreement points to a misassigned charge, an adduct or a different species.

Common precursor-level surprises

• Sodium or potassium adducts appear as peaks offset from the expected ion by a fixed amount and are frequent in unclean samples.
• Oxidation or deamidation shifts the mass by a small, characteristic amount and often appears alongside the main species.
• Truncations and deletions show a mass lower than expected by the mass of one or more residues.
• Monoisotopic versus average mass. Make sure the theoretical value you compare against uses the same convention as the measured value. High-resolution instruments resolve the monoisotopic peak; low-resolution ones often report something closer to an average.

Step 2: Understand how peptides fragment

In collision-based fragmentation, peptide bonds break along the backbone. Peaks in an MS/MS peptide spectrum commonly represent fragment ions produced by cleavage of peptide bonds, and the differences between related peaks can reveal composition and sequence. Two ion series matter most:

• b-ions contain the N-terminus of the peptide.
• y-ions contain the C-terminus.

The same source notes that mass differences between consecutive members of an ion series correspond to residue masses. That single fact is the basis of manual sequencing. Reading a ladder from one peak to the next, each gap should match one amino acid residue. A gap of about 57.02 corresponds to glycine and about 71.04 to alanine, for example.

The structures of b-ions are not as simple as textbook diagrams suggest. A perspective on peptide b-ions notes that their structures vary with ion size and peptide side chains, which is one reason fragmentation patterns differ between sequences. Other activation methods, such as electron transfer dissociation, yield different ion types (c- and z-type), and a tutorial on ETD peptide analysis stresses that every significant peak has a chemical reason, including residual precursor, neutral losses and isotopic-envelope clues.

Telling b-ions from y-ions

In a clean spectrum, y-ions are often more intense for tryptic peptides, but you should not rely on that. Practical ways to separate the series include:

1. Check which series is consistent with the precursor mass. The mass of a complementary b/y pair should add up to the precursor mass plus a small constant.
2. Look for the terminal residue. A C-terminal lysine or arginine gives a recognizable y1 ion.
3. Use labeling strategies when the question is difficult. One published approach used differential 14N/15N labeling with an N-terminal derivatization to tell b-ions from y-ions for more reliable sequencing.

Step 3: Verify the sequence against the ladder

For a synthetic peptide with a known intended sequence, the task is verification rather than discovery. You are not asking what the sequence is. You are asking whether the spectrum is consistent with the expected one. The tandem MS review for peptide and protein analysis describes how fragment-ion peaks support a sequence through the mass differences between consecutive ions, which should match the residues in the sequence.

A workable verification routine looks like this:

1. Generate the theoretical b- and y-ion masses for the expected sequence at the relevant charge states.
2. Annotate the observed spectrum against that list within your mass tolerance.
3. Walk each series residue by residue and mark where the ladder is continuous and where it breaks.
4. Confirm that the N-terminal and C-terminal ends are covered, since an unverified terminus can hide a deletion or a protecting-group remnant.
5. Account for the remaining intense peaks. Residual precursor, water or ammonia losses and internal fragments explain many of them.

The leucine and isoleucine problem

Leucine and isoleucine have identical masses, so a standard fragment ladder cannot separate them. Researchers have addressed this with multistage fragmentation: one Orbitrap study differentiated the two residues by targeting w-ions. If your sequence contains either residue at a position that matters, ask whether the method you are using can resolve it, and note the limit in your report if it cannot.

Step 4: Choose how to interpret: database search, de novo or mapping

The interpretation strategy depends on what you already know.

A study on sequencing whole proteins states that database searches are the primary route for spectra whose peptides are in the database, while de novo identification needs no database but is less accurate. Accurate precursor mass also helps searching: precision mass spectrometry can reduce the computational cost of database searches by eliminating more candidate peptides.

Software keeps improving. Cloud-based engines such as Bolt search more than 900,000 protein sequences with 41 post-translational modifications in minutes on a standard laptop, according to its authors. Newer transformer-based de novo models show strong promise, but a recent modification-focused study notes that they often struggle with the diversity and number of PTMs they can identify reliably.

For a deeper look at how these methods fit into a characterization workflow, see our overview of peptide sequence characterization methods, and for the role of reference sequence resources, peptide databases in scientific research.

Step 5: Interpret modifications and ambiguity

A mass shift on a peptide is a prompt for a question, not an answer. Localizing the shift to a residue requires fragment ions on both sides of the candidate site. A review of modification site localization scoring explains that localization relies on assignable fragment ions from cleavage between residues that could carry the modification, and that ambiguity remains when the ions do not distinguish between candidate sites, for example when diagnostic ions are absent or fragment signals are weak.

There is a search-side risk as well. Search engines may miss unpredicted modifications if those modifications were not specified as possible during the search, according to a tutorial on de novo peptide sequencing. If an intact-mass check shows an unexplained delta, rerun the interpretation with the plausible modifications or synthesis by-products enabled, rather than concluding the peptide is unidentified.

A short reporting convention helps. Write “modification present, site not localized” when the evidence supports the first and not the second, and reserve a specific residue assignment for cases where the ladder brackets it.

Common errors in peptide MS/MS interpretation

The same tutorial lists limitations that account for many wrong calls: incomplete fragmentation, search engines that leave out known fragmentation rules, and analysts who accept automated assignments without hands-on experience of how peptides fragment. A related paper makes the same point, that reliance on automated interpretation without that experience frequently leads to dubious assignments.

A checklist to catch these before a result is reported:

• Coverage gaps. Is there a stretch of the sequence with no supporting fragment? If so, the assignment there is inference, not observation.
• Unexplained intense peaks. If a high-intensity peak has no assignment, find the chemical reason before accepting the match.
• Score without inspection. A high search score does not replace looking at the annotated spectrum.
• Charge-state mistakes. An incorrect z propagates through every mass calculation.
• Convention mismatch. Mixing monoisotopic and average masses, or neutral and protonated values, produces offsets that look like real modifications.
• Isobaric residues. Leucine and isoleucine, as noted above, cannot be separated by a mass difference alone.

Documenting results for quality control

Interpretation is only useful if someone else can follow it. For each analyzed batch, a reviewer should be able to see the batch identifier, instrument and fragmentation method, charge states observed, the neutral mass found against the theoretical mass, the annotated fragment coverage, and any unresolved ambiguities. Mass spectrometry supports identity assessment and should be considered alongside chromatographic purity data. Review the methods and results actually reported in the available batch-specific Certificates of Analysis; test coverage varies by product and lot. If you are building an in-house review process, our supplier audit checklist and vendor evaluation criteria show what documentation to request. For readers new to the basics, the amino acid sequencing primer covers the foundations.

Perspective

In our experience, the weakest link in peptide documentation is rarely the instrument. It is the gap between a number on a report and the evidence behind it. A mass match tells you the right mass is present. It does not, alone, tell you the ladder supports the intended sequence.

Researchers should review the available batch-specific documentation and check which identity and purity tests were performed. At Vertex Labs, documentation availability, test coverage and reported results vary by product and lot. Use the actual laboratory report for the selected presentation as the documented baseline, and identify any additional characterization your method requires.

We would rather a laboratory re-examine the spectrum than trust a summary line, and we design our documentation to make that possible.

Vertex Labs Editorial Team

Sourcing documented peptides for your analysis

Interpretation is easier when the material arrives with batch-level documentation. Vertex Labs supplies research-use-only peptides, blends, and sterile solutions to laboratories and qualified research professionals in the United States and Puerto Rico, and we also offer custom peptide sequences and bulk procurement for institutions. Review the product page and available batch-specific COA for the selected presentation; documentation and reported results vary by lot.

Browse the research catalog or visit Vertex Labs to ask about custom sequences. Eligibility terms are explained on our Research Use Only and purchaser eligibility page. For Research Use Only. Not for human or veterinary use.

FAQ

How do I find a peptide’s mass from its m/z and charge state?

Identify the charge from the spacing of the isotopic peaks. For a positive ion containing only added protons, [M + zH]^z+, multiply the monoisotopic m/z by z and subtract z multiplied by the proton mass (1.00728). Other adducts and ionization modes require the corresponding mass adjustment. Repeat the appropriate calculation across charge states; disagreement can indicate a misassigned charge, an adduct or a different species.

What is the difference between b-ions and y-ions?

b-ions are fragments that retain the N-terminal end of the peptide, and y-ions retain the C-terminal end. Each series forms a ladder in which the mass difference between neighboring peaks corresponds to one residue, so reading both series gives two independent views of the same sequence.

Can mass spectrometry distinguish leucine from isoleucine?

Not by a standard fragment ladder, because the two residues have identical mass. Specialized multistage methods that target particular fragment types, such as w-ions, have been used to tell them apart. If the distinction matters for your work, confirm that your method can resolve it.

Why would a software match be wrong?

Automated assignments can be wrong when fragmentation is incomplete, when a modification was not included in the search, or when the software omits known fragmentation behavior. Inspecting the annotated spectrum and accounting for every significant peak is the best defense.

Sources

• 2.S Summary of Mass Spectrometry, Chemistry LibreTexts
• Precursor Resolution via Ion Z-State Manipulation, charge states in ESI-MS
• Mass Spectrum Explained, Pearson
• To b or not to b: the ongoing saga of peptide b ions
• Peptide Sequence Analysis by Electron Transfer Dissociation
• Differential 14N/15N-Labeling of Peptides Using N-Terminal Derivatization
• Tandem Mass Spectrometry for Peptide and Protein Sequence Analysis
• Discrimination of Leucine and Isoleucine in Peptides
• Template Proteogenomics: Sequencing Whole Proteins
• De Novo Peptide Sequencing and Identification with Precision Mass Spectrometry
• Bolt: a New Age Peptide Search Engine
• Modanovo: A Unified Model for Post-translational Modification de novo Sequencing
• Modification site localization scoring: strategies and performance
• Lessons in De Novo Peptide Sequencing by Tandem Mass Spectrometry

Recommended

• Peptide Sequence Characterization Methods for Researchers
• Peptide Amino Acid Sequencing: A Practical Primer for Researchers
• Peptide Terminology Beginner Checklist for Research Labs
• Peptide Sequence Verification Purchase: A Researcher’s Guide